Forge Biologics receives USFDA fast track, orphan drug, and rare pediatric disease designations

▴ Forge Biologics receives USFDA fast track, orphan drug, and rare pediatric disease designations
Forge Biologics receives FDA fast track, orphan drug, and rare pediatric disease designations for FBX-101 gene therapy for patients with krabbe disease

Forge Biologics Inc., a fully integrated clinical stage gene therapy manufacturing and development company,announced that the U.S. Food and Drug Administration has granted Fast Track, Orphan Drug, and Rare Pediatric Disease (RPD) designations to FBX-101 for the treatment of patients with Krabbe disease. Forge is now actively recruiting patients for enrollment in the RESKUE phase 1/2 clinical trial of FBX-101, a novel, first-in-human AAV gene therapy for the disease. FBX-101 is the first intravenious gene therapy program for patients with Krabbe disease and marks a major step forward in building out the company's hybrid model as a gene therapy manufacturing and development engine.

"FDA's decision to grant these designations to our first-in-human investigational gene therapy highlights the urgency of developing a treatment for Krabbe patients," said Timothy J. Miller, PhD., CEO, President and Co-Founder of Forge Biologics. "Krabbe is a devastating disease, and it is imperative to develop treatment options like FBX-101 that may address all manifestations of the disease."

Fast Track Designation is given when the FDA determines that a drug demonstrates the potential to address unmet medical needs for a serious or life-threatening disease or condition. This designation is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions, and may also allow for priority or rolling review of a company's Biologics License Application (BLA).

The FDA grants Orphan Drug designation to drugs and biological products intended for the treatment of patients with rare diseases that affect fewer than 200,000 people in the United States. RPD designation is granted by the FDA to encourage treatments for serious or life-threatening diseases primarily affecting children 18 years of age and younger and fewer than 200,000 people in the United States. On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was extended by Congress after it was scheduled to sunset in 2020. Under the newly extended RPD program, if FBX-101 is approved by the FDA, Forge Biologics will qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product.

"Infantile Krabbe is a progressive and devastating leukodystrophy," said Jessie Barnum, M.D., Assistant Professor, Department of Pediatrics, Division of Blood and Marrow Transplantation and Cellular Therapies and Principal Investigator of the FBX-101 trial at UMPC. "FBX-101 is an AAV gene therapy that has shown promising preclinical efficacy in Krabbe animal models of disease by extending survival and improving neuromuscular function when administered early in the disease course."

"The FBX-101 preclinical data brings a new wave of hope to the Krabbe community," said Anna Grantham, Director of Leukodystrophy Care Network Programs at Hunter's Hope. "These FDA designations for FBX-101 underscore a beautiful and collective effort to accelerate the timelines of bringing this potential therapy to patients who urgently need them."

"To see a promising new treatment for Krabbe receive these designations so quickly brings us one step closer to what everyone in our disease community is ultimately working towards: an FDA-approved treatment for Krabbe disease to reach the beside of all patients impacted by this disease," said Stacy Pike-Langenfeld, Director of Programs and Administration at The Legacy of Angels Foundation. "Our mission has always been to promote research to develop and enhance treatments for Krabbe disease, so it's very encouraging to see that Forge and FBX-101 have made so much progress in such a short amount of time."

Krabbe disease is a rare, inherited leukodystrophy affecting approximately 1:12,500 - 100,000 people in the U.S.A. Krabbe disease is caused by loss-of-function mutations in the galactosylceramidase (GALC) gene, a lysosomal enzyme responsible for the breakdown of certain types of lipids such as psychosine. Without functional GALC, psychosine accumulates to toxic levels in cells. The psychosine toxicity is most severe in the myelin cells surrounding the nerves in the brain and in the peripheral nervous system, eventually leading to the death of these cells. The disease initially manifests as physical delays in development, muscle weakness and irritability and advances rapidly to difficulty swallowing, breathing problems, cognitive, vision and hearing loss. Early onset or "Infantile", Krabbe disease cases usually results in death by age 2-4 years, while later onset or "Late Infantile" cases have a more variable course of progressive decline. There is currently no approved treatment for Krabbe disease.

Tags : #ForgeBiologics #LatestNewsonForgeBiologics17thFeb #LatestPharmaNews17thFeb #KrabbeDisease #LatestUSFDAApproval17thFeb

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Why is Early Intervention (EI) so important for autism?November 30, 2022
Heart failure – Symptoms, risk factors, and treatmentNovember 30, 2022
How to consume Bulletproof coffee for weight loss?November 30, 2022
MedySeva Gives New Dimension to Affordable TelehealthNovember 29, 2022
A mental healthcare revolution with Trijog November 29, 2022
Health Basix – In-school healthcare partner for your kidsNovember 28, 2022
Health-tech startup Healthkart raises Rs 536.52 Crore led by TemasekNovember 28, 2022
TummyFriendly Foods – Harmless Bio-available nutrition for little onesNovember 28, 2022
Causes, Symptoms, and Solutions to Lung Cancer November 28, 2022
5 reasons behind premature hair grayingNovember 26, 2022
Connect2MyDoctor’s cARe - Augmented Reality tool playing a crucial role in patient educationNovember 26, 2022
Bollywood Actor Kajal Aggarwal invests in D2c Startup TACNovember 26, 2022
Causes, Symptoms, Treatment, and Preventive Solutions for Ovarian Cancer November 26, 2022
Men’s health firm Bonatra raises Rs 5.5 Cr in the pre-seed funding roundNovember 25, 2022
Why is Samantha Ruth Prabhu hospitalized again in Hyderabad?November 25, 2022
RedBrick AI, a Healthtech startup, raises $4.6 million in funding from Sequoia India, Surge.November 25, 2022
Now schedule your health check-ups at a much-discounted price with MediWheelNovember 24, 2022
Kamal Haasan gets admitted to Chennai Hospital Today November 24, 2022
India's first Global Women's Health Innovation Conference to highlight the potential of Femtech & Digital InnovationsNovember 24, 2022
Pred Health - HealthTech Startup dedicated to provide Integrated care management for cancer patientsNovember 24, 2022